XML 42 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaboration Agreements and Revenues - Summary of Revenue Recognized under Agreement (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue $ 256,577 $ 212,958 $ 130,996
License Revenue [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 177,086 22,269 9,933
Development Revenue [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 114,115 125,913 121,063
Astellas Agreement [Member] | License Revenue [Member] | Japan [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 11,935 14,323 0
Astellas Agreement [Member] | License Revenue [Member] | Europe [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 117,470 0 0
Astellas Agreement [Member] | Development Revenue [Member] | Japan [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 1,222 2,400 1,588
Astellas Agreement [Member] | Development Revenue [Member] | Europe [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 28,172 18,503 18,523
AstraZeneca Agreements [Member] | China [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 90 0 0
AstraZeneca Agreements [Member] | License Revenue [Member] | U.S./RoW and China [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 47,681 7,946 9,933
AstraZeneca Agreements [Member] | Development Revenue [Member] | U.S./RoW and China [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue $ 84,629 $ 104,970 $ 100,928